PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
Czasopismo
2014 | 10 | 1 |
Tytuł artykułu

Use of antiviral therapy in patients with chronic hepatitis C

Treść / Zawartość
Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
Introduction: The presence of background HCV infection cannot be overestimated in view of the prevalence of chronic hepatitis C and the risk of adverse outcomes of this disease. Purpose of this study was to evaluate the effectiveness of the combined use of antiviral therapy (Roferon + Vero-Ribavirin) and resort factors in patients with chronic hepatitis C in the phase of replication. Material and methods: We observed 48 patients with chronic hepatitis C; the minimum level of activity of the process defined the phase of replication. Markers of HCV infection were determined by enzyme linked immunosorbent assay (ELISA) (a-HCV and HCV-Ig M). HCV RNA was determined twice by the polymerase chain reaction (PCR). Genotyping of hepatitis C virus was performed. Biochemical blood analysis and the study of HCV infection markers were carried out four times. Results of therapy were assessed immediately after the end of the resort (spa) treatment, then at 3, 6 and 12 months after starting treatment. At 12 months after starting treatment, all the observed patients had persistent clinical and biochemical remission. Elimination of the virus from the blood was noted in 56% of the control group and 74% of patients in the study group. Conclusions: For patients with moderately active HCV, the replication phase was characterized by asthenic-vegetative syndrome (100% of patients) with severe depression (22.92%), pain (77.08%) and dyspeptic syndrome (33.33%), moderate hypertransferaseemia (100%), slightly pronounced cholestasis (33% of patients), and signs of mesenchymal- inflammatory response.
Wydawca

Czasopismo
Rocznik
Tom
10
Numer
1
Opis fizyczny
Daty
otrzymano
2014-05-14
zaakceptowano
2014-09-30
online
2015-03-20
Twórcy
  • Ukrainian
    scientific research institute of medical rehabilitation and
    curortology Ministry of Health Ukraine, Odessa, Ukraine
autor
  • Ukrainian
    scientific research institute of medical rehabilitation and
    curortology Ministry of Health Ukraine, Odessa, Ukraine
  • Ukrainian
    scientific research institute of medical rehabilitation and
    curortology Ministry of Health Ukraine, Odessa, Ukraine
  • Faculty of Physical Culture, Health and Tourism, Kazimierz
    Wielki University, Bydgoszcz, Poland
  • Faculty of Physical Culture, Health and Tourism, Kazimierz
    Wielki University, Bydgoszcz, Poland
  • Faculty of Physical Culture, Health and Tourism, Kazimierz
    Wielki University, Bydgoszcz, Poland
  • Faculty of Physical Culture, Health and Tourism, Kazimierz
    Wielki University, Bydgoszcz, Poland
  • Faculty of Physical Culture, Health and Tourism, Kazimierz
    Wielki University, Bydgoszcz, Poland
  • Faculty of Physical Culture, Health and Tourism, Kazimierz
    Wielki University, Bydgoszcz, Poland
  • Faculty of Physical Culture, Health and Tourism, Kazimierz
    Wielki University, Bydgoszcz, Poland
autor
  • Faculty of Physical Culture,
    Health and Tourism, Kazimierz Wielki University, ul. Ogińskiego
    16, 85-092 Bydgoszcz, Poland
Bibliografia
  • [1] Kharchenko NV, Babak OJ. Gastroenterology. K. 2007; 720.[Harchenko N.V., Babak O.Ja., Gastroenterologіja.- K.: 2007. -720 s.] In Russian
  • [2] Degtyareva II. Clinical gastroenterology. Medical InformationAgency 2004; 616. [Degtjareva I.I. Klinicheskaja gastrojenterologija.– M.: Medicinskoe informacionnoe agentstvo, 2004.– 616 s.] In Russian
  • [3] Dragomiretskaya NV. Early resort rehabilitation and restorativetreatment in gastroenterology: Monograph. ORIDU Nadu,Odesa, 2007; 176. [Dragomireckaja N.V. Rannja kurortnareabіlіtacіja ta vіdnovljuval‘ne lіkuvannja v gastroenterologії:Monografіja. - Odesa, ORІDU NADU, 2007. - 176 s.] In Russian
  • [4] Dragomiretskaya NV. The effectiveness of health. Resort rehabilitationof patients with chronic hepatitis C. Int J Immunoreab2001; 3: 112. [Dragomireckaja N.V. Jeffektivnost‘ kurortnojreabilitacii bol‘nyh hronicheskim gepatitom S. Internationaljournal on immunoreabilitation. May 2001. – Vol. 3, 2. – P .112.] In Russian
  • [5] Dragomiretskaya NV, Malykhina TI. Izha AN. The use oflow-mineralized mineral water and cytrarginine in complextreatment of patients with chronic hepatitis C. Rus J GastroenterolHepatol Coloproctol 2005; 1: 11. [Dragomireckaja N.V.,Malyhina T.I., Izha A.N. Primenenie malomineralizovannojmineral‘noj vody i citrarginina v kompleksnom lechenii bol‘nyhhronicheskim gepatitom S. Rossijskij zhurnal gastrojenterologii,gepatologii, koloproktologii. – 2005. - # 1. – S. 11.] InRussian
  • [6] Nikitin IG. Treatment of chronic hepatitis C: yesterday,today and tomorrow. Russian Journal of Gastroenterology,Hepatology, Coloproctology. - 2002. - # 6. - S. 11-16. [Nikitin I.G.Lechenie hronicheskogo gepatita S: vchera, segodnja, zavtra.Rossijskij zhurnal gastrojenterologii, gepatologii, koloproktologii.– 2002. - # 6. – S. 11-16.] In Russian
  • [7] Podymova SD. Liver disease: a guide. - 4th ed. Rev. and add.- Moscow: JSC „Publishing House“ Medicine“, 2005. - 768.[Podymova S.D. Bolezni pecheni: rukovodstvo. - 4-e izd.,pererab. i dop. - M.: OAO «Izdatel‘stvo «Medicina», 2005. -768 s.] In Russian
  • [8] Fedorchenko SV. Chronic HCV –infection. Monograph. - K.: TNI„Medicine“, 2010. - 272. [Fedorchenko S.V. Hronicheskaja HCV-infekcija: monografija. – K.: VSI «Medicina», 2010. – 272 s.] InRussian
  • [9] Kharchenko NV. Treatment of patients with chronic hepatitis C.Modern gastroenterology gepatology. -2000. - # 2. - S. 60-63.[Harchenko N.V. Lechenie bol‘nyh hronicheskim gepatitom S.Suchasna gastroenterologіja і gepatologіja. – 2000. - # 2. – S.60-63.] In Russian
  • [10] Affonso de Araujo FS, Courtouke C, Barone AA. Hepatitis C:shorter and better? Brasil J Inf Dis 2007; 11: 118-124
  • [11] Andriulli A, Mangia A, Iacobellis A, et al. Meta-analisis: the outcome of antiviral therapy in HCV genotype 2 and 3 pa¬tientswith chronic hepatitis. Aliment Pharmacol Ther 2008; 28:397-404[Crossref]
  • [12] Hadziyannis S, Cheinquer H, Morgan T, et al. Prospectiveevaluation of early virologic response associated withpeginterferon alfa-2a (PEGASIS) plus ribavirin therapy from aphase III, randomized, double-blind study examinity the effectof treatment duration and ribavirin dose. American Associationfor the study of Liver disease, 52nd Annual Meeting, November9-13th 2001, Dallas, USA
  • [13] Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis,management and treatment of hepatitis C: an up date.Hepatology 2009; 49: 1336-1374
  • [14] Mangia A, Minerva N, Bacca D, et al. Individualized treat¬mentduration for hepatitis C genotype 1 patients: randomizedcontrolled trial. Hepatology 2007; 47: 43-50[Crossref]
  • [15] Poynard T, Mc Hutchinson JG, Goodman Z, et al. Isan «a lacarte» combination interferon alfa-2b plus ribavirin regimenpossible for the first line treatment in patients with chronichepatitis C? The ALGOVIRC Project Group. Hepatology 2000; 31:211-218[Crossref]
  • [16] Wong JB, Mc Quillan GM, Mc Hutchinson JG, et al. Esti¬matingfuture hepatitis C morbidity, mortality and cots in the UnitedStates. Am J Public Health 2000; 90: 1562-1569
  • [17] Sikorska K, Stalke P, Izycka-Swieszewska E, Romanowski T,Bielawski K. The role of iron overload and HFE gene mutationsin the era of pegylated interferon and ribavirin treatment ofchronic hepatitis C. Med Sci Monit 2010; 16(3):CR137-143
  • [18] Pawlowska M, Pilarczyk M, Halota W. Virologic response totreatment with Pegylated Interferon alfa-2b and Ribavirinfor chronic hepatitis C in children. Med Sci Monit 2010;16(12):CR616-621
  • [19] Dragomiretskaya N., Shevchenko N., Izha G., ZabolotnayaI., Kalinichenko N., & Zukow, W. Application of natural andphysical factors is in treatment of patients with chronic viralhepatitis S - ground of the use. Journal of Health Sciences.2013; 3(4): 153-163
  • [20] Dragomiretskaya N., Zabolotnaya I., Izha A., Shevchenko N., &Kalinichenko N. Results and prospects of further developmentof early rehabilitation and recovery treatment health patientswith gastroenterological profile in Ukraine (native studies).2012; 2(6): 42-54
  • [21] Dragomiretska N.V., Izha G.M., Zabolotna I.B., KalinichenkoM.V., Shevchenko N.O. Clinical experience of complexapplication of antiviral therapy, natural and preformed physicalfactors in patients with chronic hepatitis C. Gastroenterologia.2013; 47(1):. 1:60-64. Actual problems of transport medicine.2012; 4(30):117-123
  • [22] Dragomiretskaya N.V., Fedirko A.M. Irritable bowel syndrome:an opportunity for new approaches of treatment. Medicalrehabilitation, curortology, physiotherapy. 2011; 1(65):31-35
  • [23] Dragomiretskaya N.V., Zabolotnaya I.B., Malykhina T.I., IzhaA.N., Shevchenko N.A., Kalinichenko N.V. Viral hepatitis:standard therapy and usage of natural factors. Sovremennayagastroenterologia. 2011; 6 (62):92-98
Typ dokumentu
Bibliografia
Identyfikatory
Identyfikator YADDA
bwmeta1.element.-psjd-doi-10_1515_med-2015-0032
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.